In Q4 2025, Novo Nordisk reported a decline in revenue and profitability year over year, driven by weaker US performance and pricing pressure, partially offset by continued strength in obesity care.

Novo Nordisk delivered solid sales growth in Q3 2025, especially in obesity care, but saw a 27% drop in net income primarily due to DKK 9 billion in restructuring charges tied to a company-wide transformation.

Novo Nordisk delivered solid financial performance in Q2 2025, with double-digit growth in revenue, operating profit, and net income. Obesity care was the main growth engine, offsetting challenges related to compounded GLP-1 competition in the U.S.

Novo Nordisk delivered a robust Q1 2025, with sales growing 19% and net profit rising 28%, fueled by continued demand for GLP-1 therapies and expanding market presence in obesity care.